While various changes in the tumor margin did not show individual associations with NAT efficacy, the NMHR group displayed a higher proportion of multiple changes in the margin (90.00% vs. 65.79%, p = 0.012) than the MHR group. The gene discussed is BRD2; the disease is neoplasm.